[
  {
    "My Clinical Question (condition: Void Trials/Catheter Questions)": "***"
  },
  {
    "My most current assessment of this problem can be found in the note dated": "{Today/***}"
  },
  {
    "In your clinical question, or current note, please include information on": {
      "Assessments": [
        {
          "Reason and duration of urinary catheter": "***"
        },
        {
          "Reason for void trial": "***"
        },
        {
          "Previous void trials": "***"
        },
        {
          "What medications is the patient on": "***"
        }
      ],
      "Diagnostics": [
        {
          "Urinalysis": "***"
        },
        {
          "Urine culture": "***"
        }
      ],
      "Clinical Pearls": [
        {
          "Acute urinary retention (AUR) in men with BPH or presumed BPH is treated with urethral catheterization for bladder decompression. An alpha-1-adrenergic antagonist (eg, alfuzosin 10 mg daily) initiated at the time of initial catheterization. Ongoing combination treatment is generally necessary to prevent recurrence of AUR": "***"
        },
        {
          "In men with AUR due to BPH, removal of the catheter after a period of time (\"trial without catheter\" or TWOC) results in successful spontaneous micturition in up to 40 percent of patients, although recurrent AUR is common. We suggest a trial of catheter removal in one to two weeks. For patients who fail the initial TWOC, we advise a second trial of TWOC after an additional two weeks with the catheter": "***"
        },
        {
          "Men with BPH who fail a second TWOC may need surgical therapy. A urodynamic evaluation is advised prior to prostate surgery for patients who have experienced AUR": "***"
        }
      ]
    }
  }
]
